Vertex executives warned that Casgevy, its curative treatment for sickle cell disease, would be slow to reach patients. But ...
Zacks Investment Research on MSN
Vertex Pharmaceuticals (VRTX) earnings expected to grow: What to know ahead of next week's release
The market expects Vertex Pharmaceuticals (VRTX) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2025. This widely-known ...
3d
Is Vertex Pharmaceuticals (VRTX) Pricing Reflect Long Term Cash Flow Potential After Recent Pullback
Wondering if Vertex Pharmaceuticals at around US$470 a share is offering fair value, or if you are paying up for quality, you ...
Zacks Investment Research on MSN
Is trending stock Vertex Pharmaceuticals Incorporated (VRTX) a buy now?
Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...
KING OF PRUSSIA, Pa., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), a leading ...
Jupiter Endovascular announced that it completed patient enrollment in the SPIRARE II pivotal clinical trial evaluating its Vertex system.
China-based biologics CDMO WuXi Biologics (HKEX: 2269) has signed a license and research services agreement with US biotech Vertex Pharmaceuticals (Nasdaq: VRTX) covering a preclinical trispecific ...
Vertex Pharmaceuticals stock was heading for a double-digit gain this year until recent weeks. The company is approaching an important turning point -- one that could set the tone for revenue growth.
Vertex Flooring Presents High-Performance SPC Flooring Designed for Stability, Style, and Durability HOLLISTON, MA, ...
The biotech could be on the verge of expanding its lineup and entering a new era of growth.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results